GlassScriptPhysician profile
Augustus Mazzocca
NPI 1902802903
$1,044,054.79
in general payments reported to CMS, 2019-2025
18 companies · $60K in 2025
The $60K reported for 2025 was more than what 96% of Sports Medicine (Orthopaedic Surgery) providers received nationally (typical 2025 total: $686).
See the full distribution for Sports Medicine (Orthopaedic Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228K · 2020: $192K · 2021: $245K · 2022: $170K · 2023: $93K · 2024: $56K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $111K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Travel and Lodging: $19K · Food and Beverage: $3,886 · Royalty Or License: $1,996 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $111,100.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,395.00 |
| Travel and Lodging | $19,083.05 |
| Food and Beverage | $3,886.42 |
| Royalty Or License | $1,996.49 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $956,132.96 | 2019-2025 | Arthrex |
| Restor3d, INC. | $70,555.86 | 2022-2025 | |
| Kairos Surgical INC | $14,031.41 | 2020-2024 | |
| Synthes Gmbh | $739.08 | 2023 | |
| Medacta USA, INC. | $571.96 | 2025 | Primary Shoulder |
| Stryker Corporation | $393.02 | 2021-2025 | Blueprint Patient Specific Instrumentation, Alphavent, Aequalis Perform |
| Smith+Nephew, INC. | $316.41 | 2022-2025 | Bioinductive Implant With Arthroscopic Delivery System - Medium, Bone Anchors With Arthroscopic Delivery System, Aetos Shoulder System |
| Catalyst Orthoscience | $295.96 | 2023-2024 | Csr & R1 Reverse Total Shoulder Systems, R1 Reverse Total Shoulder, Archer 3d Software |
| Exactech, INC. | $192.44 | 2025 | |
| Arthrosurface Incorporated | $158.30 | 2020 | |
| Medinc of Texas | $150.61 | 2025 | |
| Bone Support INC. | $143.65 | 2024 | Cerament G, Ceramentbone Void Filler |
| Alpha Orthopedic Systems | $116.64 | 2021 | |
| Baxter Healthcare | $115.38 | 2025 | Floseal |
| Active Medical, LLC | $57.84 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $45.62 | 2025 | Na |
| Avanos Medical | $23.58 | 2021 | |
| Trimed, INC. | $14.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustus Mazzocca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.